CUPIDO project deliverables
The page lists 15 deliverables related to the research project "CUPIDO".
List of Deliverables
| title and desprition | type | last update |
|---|---|---|
Extended model, describing relationship between FeCaPs and deposition site when exposed to an external magnetic field (M12)Definition of FeCaP deposition and flow at multiple scales taking into account various physico-chemical parameters such as particle size distribution, shape, magnetic susceptibility, etc Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Distribution of electromagnetic fields in the target area due to the drug targeting systemsComparison of different system solutions able to generate the magnetic field gradient (or the magnetic field) needed to guide the FeCaPs at the level of the heart tissues Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Visual identity kit (M12)Creation of a visual identity for the project, including the project logo and document templates, with the development of promotional and informational materials contributing to the overall perception of the project and its uniform impression. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
In vivo assessment of the studied nanopartilces using different imaging modalities (M12)In vivo assessment of loaded and unloaded dpCaPs and FedpCaPs for a full spectrum of biocompatibility, toxicity, blood-interaction, air/blood flow-interaction at pulmonary barrier, inflammatory responses, and pharmacokinetics. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Summary of annual workshops and networking events building communities (M12)Generation of period report regarding CUPIDO major results and activites Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Web portal, social mediaFacilitate the communication of information to the media and through the media to become the key multiplier to reach the wider public. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Press releases (M3)Outline what CUPIDO is, what it will do, who it is intended to, the innovation it will bring and its benefits. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
In vitro assessment of nanoparticle behavior at/across the pulmonary barrier (M12)In vitro assessment of loaded and unloaded dpCaPs for a full spectrum of biocompatibility, toxicity, and air/blood flow-interaction at pulmonary barrier. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Extension of open-source flow simulation framework to also include porous media flow. Establish relationship between different nanoparticles and deposition sites in both small and large animal models (M18)Definition of CaP deposition and flow at multiple scales taking into account various physico-chemical parameters such as particle size distribution, shape, magnetic susceptibility, etc Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Summary of annual workshops and networking events building communities (M18)Generation of period report regarding CUPIDO major results and activites Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Aptamer-mediated guidance of CaP (M12)CaP functionalized with aptamers for improved myocardial-specific targeting Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Press releases (M12)Outline what CUPIDO is, what it will do, who it is intended to, the innovation it will bring and its benefits. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
Functional assessment (compatibility, physic-chemical and biological stability) of CaP restoration and drug releaseThe biological activity of the powders and the reconstitution of CaP population will be thoroughly evaluated in vitro in cardiomyocyte lines (HL-1), adult primary mouse cardiomyocytes and human induced pluripotent stem cells (hiPS)-derived cardiomyocytes. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
E-newsletter (M12)Yearly update of the main project contacts and to external subscribers Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |
EMD-mediated guidance of FeCaP (M12)Optimized FeCaPs for electromagnetic-mediated guidance to the heart via an electromagnetic device. Programme: H2020-EU.2.1.2. - Topic(s): NMBP-10-2016 |
Documents, reports | 2020-04-08 |